Altium Capital Management LP Invests $2.24 Million in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Altium Capital Management LP bought a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 2nd quarter, HoldingsChannel reports. The fund bought 213,533 shares of the company’s stock, valued at approximately $2,238,000.

Several other large investors have also bought and sold shares of FULC. Acadian Asset Management LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter worth about $41,000. Cubist Systematic Strategies LLC increased its position in shares of Fulcrum Therapeutics by 570.6% during the first quarter. Cubist Systematic Strategies LLC now owns 3,655 shares of the company’s stock worth $43,000 after acquiring an additional 3,110 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Fulcrum Therapeutics during the second quarter worth about $53,000. Citigroup Inc. increased its position in shares of Fulcrum Therapeutics by 297.4% during the second quarter. Citigroup Inc. now owns 6,919 shares of the company’s stock worth $73,000 after acquiring an additional 5,178 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Fulcrum Therapeutics during the second quarter worth about $122,000. 64.80% of the stock is owned by institutional investors.

A number of equities research analysts have issued reports on the stock. SVB Leerink reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Fulcrum Therapeutics in a research report on Sunday, August 15th. Credit Suisse Group upped their price objective on shares of Fulcrum Therapeutics from $20.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 11th. HC Wainwright upped their price objective on shares of Fulcrum Therapeutics from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 17th. Piper Sandler boosted their target price on shares of Fulcrum Therapeutics from $20.00 to $46.00 and gave the company an “overweight” rating in a research note on Tuesday, August 17th. Finally, Morgan Stanley upgraded shares of Fulcrum Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $12.00 to $34.00 in a research note on Wednesday, August 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $35.57.

Shares of FULC stock traded down $0.60 during trading on Thursday, reaching $27.16. 6,452 shares of the company’s stock traded hands, compared to its average volume of 631,423. The firm’s 50-day moving average is $25.38 and its 200 day moving average is $15.27. Fulcrum Therapeutics, Inc. has a 1 year low of $6.85 and a 1 year high of $33.10.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Tuesday, August 10th. The company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.05. The company had revenue of $4.38 million for the quarter, compared to analysts’ expectations of $2.69 million. Fulcrum Therapeutics had a negative net margin of 481.07% and a negative return on equity of 66.84%. On average, equities analysts predict that Fulcrum Therapeutics, Inc. will post -2.68 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.

Featured Article: What is Depreciation?

Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC).

Institutional Ownership by Quarter for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.